Tweets by @tcochrane
-
Your 401(k)'s Comeback Underscores the Risks of Fed's Easy-Money Policy https://t.co/l3HvWGWlab via @business -
Top 100 CEO Retirement Savings Equals 41% of U.S. Families https://t.co/YVtTAUCrLR via @business
-
U.S. Sen. Warren: ‘Kickbacks’ create conflicts for annuity sales agents https://t.co/Wcgs3bf6EX via @WSJ
-
Amgen's First-of-its-Kind Skin Cancer Drug Wins U.S. Approval https://t.co/w9YEqjRIXy via @business
-
Stem cell research opens door to new diabetes treatments https://t.co/Ujt7Valp6a via @medical_xpress
-
Hilarious: Guys Retire to Hang With Their Wives. And the Wives? https://t.co/dbvj2P7GVi via @business
-
Has FDA approval of 23andMe tests put the personal genetics revolution back on track? https://t.co/gzudPSyyeH via @GeneticLiteracy
-
23andMe Will Resume Giving Users Health Data https://t.co/WMoXm7LdfS
-
New Microscopic Imaging Technology Reveals Origins of Leukemia https://t.co/oRVdU86tOo
-
Researchers identify potential alternative to CRISPR-Cas genome editing tools https://t.co/YwXeGzTGzJ
-
A CEO's View On Amgen's Quest To Pioneer The Next Cancer Immunotherapy via @forbes https://t.co/4zfIWQ5hOH
-
How Much Does Venture Capital Drive the U.S. Economy? https://t.co/1yUFuSdl5B via @stanfordbiz
-
The New Fiduciary Rule and Annuities https://t.co/UGPbZ4c5th
-
The new math of delaying Social Security benefits https://t.co/mHQfpIff50 via @WSJ
-
Why are people still dying of cancer? https://t.co/JFQIUqBcM9 via @aeonmag
-
Japan’s longevity champs may not win even the silver anymore https://t.co/mfMDy9JrPR via @WSJ
-
Clients Need To Understand Longevity Risk To Their Portfolios https://t.co/kTDlr0YQeO via @sharethis
-
The 401(k) Crisis Is Getting Worse https://t.co/Qen2H9Qmjc via @business
-
New research raises hope for novel cancer immunotherapy https://t.co/h3Xc8mtiyU
-
Immunotherapy Tightens the Siege of Solid Tumors | Insight & Intelligence™ | GEN https://t.co/9VKyblHcLg via @genbio
